Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Biomedtracker

Biomedtracker 2018 Early Outlook Report

28 Jul 2022

What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

Datamonitor Healthcare

Japan Pharma Outlook Webinar Recording

By Ian Haydock 15 Jun 2022

Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.

Scrip

Scrip Asia 100 Report Extract

26 Mar 2021

Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.

Exploring Basket and Umbrella Oncology Trials

27 Nov 2020

To increase flexibility and efficiency in drug development, master protocols have emerged as an innovative clinical trial design, including basket and umbrella trials. Learn more about how these approaches are being used within oncology research through an overview of the clinical landscape, trial outcomes and trends.

Depression New Insights Shifting the Treatment Paradigm Whitepaper

27 Nov 2020

Depression affects approximately 1 in 6 Americans, with 10 – 30% of depression patients becoming treatment-resistant. Find out what the pipeline looks like for depression and what the emerging strategies in this area are. This data-packed whitepaper from Informa Pharma Intelligence can now be downloaded – free.

In Vivo

Curing What Hinders Alzheimer’s Drug Development

By Rachel Laing, Alessia Deglincerti, Mark Ratner 27 Nov 2020

Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

Trialtrove

2018 Clinical Trials Roundup: Surveying the Landscape of 2018 Trial Starts

27 Nov 2020

See last year’s clinical trial activity through the eyes of our expert analysts and get a better sense of where the industry is headed. This new whitepaper is the annual analysis of Phase I-III clinical trials, from Citeline’s Trialtrove, and reveals the priorities and strategies of the biopharma industry.  

Datamonitor Healthcare

Webinar: Outlook for NASH Therapies and Market Dynamics

By Joseph Haas 04 Nov 2019

Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.